The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer

  • STATUS
    Recruiting
  • End date
    Dec 31, 2025
  • participants needed
    627
  • sponsor
    Fudan University
Updated on 5 August 2020
cancer
metastasis
adenocarcinoma
induction chemotherapy
primary tumor
systemic chemotherapy
colon cancer
tumor resection
adenocarcinoma of colon
metastatic colon cancer
adenocarcinoma of the colon
mfolfox6
xelox
stage iv colon cancer

Summary

The aim of this trial is to evaluate the value of palliative primary tumor resection in colon cancer patients with initially unresectable metastases and a positive response to induction chemotherapy which depends on gene testing. The primary endpoint is to evaluate overall survival.

Details
Condition Surgery, Surgical aspects, Surgery, Metastatic Colon Cancer
Age 18years - 75years
Treatment XELOX, resection of primary tumor, mFOLFOX6
Clinical Study IdentifierNCT04416854
SponsorFudan University
Last Modified on5 August 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

years old
ECOG (Eastern Cooperative Oncology Group) 0-1 and expected survival period for 6 months or more
Pathological diagnosis of colon cancer adenocarcinoma
At least one measurable objective tumor lesions which could be evaluated
Primary and metastatic tumors exist at the same time, and distant metastases are not resectable
ANC1.5 _109/LPLT90_ 109/LHB90g/LTBI1.5(UNL); ALTAST2.5ULNCr1.0(ULN) screening within 7 days
No systemic chemotherapy
Patients with voluntary participation, and sign the informed consent

Exclusion Criteria

Operation intervention required for perforation, bleeding and obstruction of intestinal cavity
Multiple primary colorectal carcinoma
Malignant peritoneal effusion or metastatic carcinoma of the peritoneum
Uncontrolled pleural effusion
Malignant tumour of the past five years with other organizations to source, but the full treatment of cervical carcinoma in situ and except skin basal cell carcinoma and squamous cell carcinomas
With brain metastasis or meningeal metastasis
Pregnancy or breast-feeding women
Alcohol or drug addictions
There is an important organ failure or other serious diseases, including coronary artery disease, symptomatic cardiovascular disease or myocardial infarction within 12 months; serious neurological or psychiatric history; severe infection; actively disseminated vascula blood coagulation
Clear my responses

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.